Anti‐SSA/Ro autoantibodies serve as crucial serological markers across a spectrum of systemic autoimmune diseases, encompassing idiopathic inflammatory myopathies, systemic lupus erythematosus (SLE), Sjögren's syndrome, neonatal lupus, and primary biliary cirrhosis (Franceschini and Cavazzana, 2005[20]; Yoshimi et al., 2012[46]). Here, TRIM21 is linked to systemic lupus erythematosus.